CAJ | 학술논문

目的:通过与静脉辅助化疗对照,观察经肝动脉灌注联合静脉辅助化疗对Ⅲ期结直肠癌术后肝转移、无病生存期及总生存期的影响.方法:2002年1月至2006年3月,21例Ⅲ期结直肠癌患者作为治疗组,术后给予肝动脉灌注FUDR联合静脉应用草酸铂化疗,同期对照21例Ⅲ期结直肠癌患者,术后给予草酸铂联合CF/5-FU静脉化疗.主要观察终点为肝转移率及DFS,次要终点为OS和用药安全性.结果:中位随访65(9~119)个月,治疗组肝转移发生率较低(9.5% vs.28.6%,P=0.109),肺转移发生率略高(28.6% vs.14.3%,P=0.256).2组5年DFS(38.1% vs.42.9%,P=0.671)及OS(47.9% vs.45.0%,P=0.784)无统计学差异.化疗副反应多为Ⅰ~Ⅱ度血白细胞减少、恶心呕吐及感觉神经障碍.结论:Ⅲ期结直肠癌术后给予经肝动脉联合静脉系统化疗,与静脉化疗相比,可能会降低肝转移的发生率,DFS及OS无统计学差异,化疗副反应较轻,可耐受.
목적:통과여정맥보조화료대조,관찰경간동맥관주연합정맥보조화료대Ⅲ기결직장암술후간전이、무병생존기급총생존기적영향.방법:2002년1월지2006년3월,21례Ⅲ기결직장암환자작위치료조,술후급여간동맥관주FUDR연합정맥응용초산박화료,동기대조21례Ⅲ기결직장암환자,술후급여초산박연합CF/5-FU정맥화료.주요관찰종점위간전이솔급DFS,차요종점위OS화용약안전성.결과:중위수방65(9~119)개월,치료조간전이발생솔교저(9.5% vs.28.6%,P=0.109),폐전이발생솔략고(28.6% vs.14.3%,P=0.256).2조5년DFS(38.1% vs.42.9%,P=0.671)급OS(47.9% vs.45.0%,P=0.784)무통계학차이.화료부반응다위Ⅰ~Ⅱ도혈백세포감소、악심구토급감각신경장애.결론:Ⅲ기결직장암술후급여경간동맥연합정맥계통화료,여정맥화료상비,가능회강저간전이적발생솔,DFS급OS무통계학차이,화료부반응교경,가내수.
Objective: This study aims to investigate whether postoperative hepatic arterial infusion combined with systemic adjuvant chemotherapy is more effective compared with systemic adjuvant chemotherapy alone in terms of survival and liver metastasis for patients with stage Ⅲ colorectal cancer. Methods: From January 2002 to March 2006, 21 patients with stage Ⅲ colorectal cancer were assigned to postoperative locoregional chemotherapy with fluorodeoxyuridine and systemic adjuvant chemotherapy with oxaliplatin (treatment group). Another group of 21 patients were assigned to the systemic adjuvant chemotherapy with oxaliplatin as well as fluorouracil and folinic acid (control goup). The primary endpoint of the observation included 5-year disease-free survival (DFS) and liver metastasis. The secondary endpoint was the overall survival (OS) and toxic effects. Results: Median follow-up was 65 months (range: 9 months to 119 months). The incidence rate of liver metastasis in patients who underwent hepatic arterial infusion and systemic chemotherapy was 9.5%, whereas that in patients who underwent systemic chemotherapy alone was calculated at 28.6% (P=0.109). By contrast, the incidence of lung metastasis was relatively higher; however, the difference was not significant (28.6% vs. 14.3%, P =0.256). No significant difference in the 5-year DFS (38.1% vs. 42.9%, P=0.671) and the 5-year OS (47.9%vs. 45.0%, P=0.784) was indicated between the two groups. Toxicities such as reduction in leukocytes as well as nausea and peripheral neurosensory toxicity were mild and could be treated by medication. Conclusion: Postoperative hepatic arterial infusion combined with systemic chemotherapy can possibly reduce the occurrence of liver metastasis, but may add no further benefit to the DFS and OS of the patients with stage Ⅲ cancer obtaining systemic chemotherapy alone. The toxicities were mild and tolerable.